SCHEMBL16486289

SCHEMBL16486289

Cc1[nH]c(C=C2C(=O)Nc3ccc(C(=O)O)cc32)c(C)c1C(=O)N[C@H](C)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GRK5 P34947 14/20 0.61
▸ KDR P35968 3/20 0.59
▸ PDGFRB P09619 3/20 0.59
▸ FGFR1 P11362 2/20 0.59
▸ ALK Q9UM73 1/20 0.59
▸ PRKAA2 P54646 3/20 0.54
▸ PRKAA1 Q13131 3/20 0.54
▸ TLK2 Q86UE8 1/20 0.53
▸ HDAC3 O15379 1/20 0.51
▸ HDAC4 P56524 1/20 0.51
▸ HDAC1 Q13547 1/20 0.51
▸ HDAC7 Q8WUI4 1/20 0.51
▸ HDAC2 Q92769 1/20 0.51
▸ HDAC10 Q969S8 1/20 0.51
▸ HDAC11 Q96DB2 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51
▸ HDAC9 Q9UKV0 1/20 0.51
▸ HDAC5 Q9UQL6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16490717 1.00 GRK5 (0.61) GRK5KDRPDGFRBFGFR1ALK
SCHEMBL16568016 1.00 GRK5 (0.61) GRK5KDRPDGFRBFGFR1ALK
SCHEMBL16490713 0.90 GRK5 (0.58) GRK5KDRPDGFRBFGFR1ALK
SCHEMBL16490747 0.88 GRK5 (0.77) GRK5
SCHEMBL16568036 0.88 GRK5 (0.77) GRK5
SCHEMBL16486269 0.88 GRK5 (0.77) GRK5
SCHEMBL16490745 0.86 ALK (0.78) GRK5KDRPDGFRBFGFR1ALK
SCHEMBL16486529 0.86 ALK (0.78) GRK5KDRPDGFRBFGFR1ALK
SCHEMBL16567988 0.85 GRK5 (0.59) GRK5KDRPDGFRBFGFR1ALK
SCHEMBL16486655 0.85 GRK5 (0.59) GRK5KDRPDGFRBFGFR1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US claimed
WO-2015022437-A1 INDOLINONE DERIVATIVES AS GRK5 MODULATORS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-02-19 — — WO claimed
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US disclosed
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-03-19 — — US disclosed
WO-2015022437-A1 INDOLINONE DERIVATIVES AS GRK5 MODULATORS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY GCKR, GRK4, GRK5 GRK5 3/4885KDR 1123/4885PDGFRB 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback